

Nanexa is granted patent in India

Nanexa AB (publ) today announced that the company has been granted a patent in India relating to its PharmaShell® technology. This patent covers the relevant manufacturing method, coated drug particles that result therefrom, and pharmaceutical composition containing those particles.

"I am pleased to note that we have now established strong global patent protection for PharmaShell. Today's announcement is an important milestone for which we have worked long and hard. India is both a large production country and a significant market for pharmaceuticals, and it is important that we obtained strong patent protection there as well", said David Westberg, CEO of Nanexa.

The PharmaShell patent is already granted in the US, Japan, Korea, China, Canada and in European countries. With the approval in India, Nanexa now has patents in all countries where it applied for patent protection.

For additional information, please contact:

David Westberg – CEO, Nanexa AB (publ)

Phone: +46 70 942 83 03

Email: david.westberg@nanexa.se

www.nanexa.com

Erik Penser Bank is the company's Certified Adviser and can be reached on +46 8 463 83 00, email: certifiedadviser@penser.se

About Nanexa AB (publ)

Nanexa is a pharmaceutical company developing injectable drug products based on the proprietary and innovative drug delivery system PharmaShell® – the high drug load delivery system enabling the next generation long-acting injectables through atomic layer precision. Nanexa develops its own products and also has collaboration agreements with several pharma companies, among others Novo Nordisk and AstraZeneca.

Nanexa's share is listed on Nasdaq First North Growth Market in Stockholm (NANEXA).

Attachments

[Nanexa is granted patent in India](#)